Nanomedicine therapeutic approaches to overcome cancer drug resistance

Advanced Drug Delivery Reviews

Volumn 65, Issue 13-14, 2013, Pages 1866-1879

  Markman, Janet L ^a   Rekechenetskiy, Arthur ^a   Holler, Eggehard ^a,b,c   Ljubimova, Julia Y ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Arrogene Inc   (United States)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Drug delivery; Nanobiopolymers; Nanodrug; Tumor multidrug resistance

Indexed keywords

CONTROLLED DRUG DELIVERY; DISEASES; DRUG DELIVERY; LIPOSOMES; MEDICAL NANOTECHNOLOGY; MICELLES; TUMORS;

ADVANCED DESIGNS; DRUG RESISTANCE; MEDICAL SCIENCE; METALLIC NANOPARTICLES; MULTIDRUG RESISTANCE; NANOBIOPOLYMERS; NANODRUG; POLYMER CONJUGATE;

TARGETED DRUG DELIVERY;

ANTISENSE OLIGONUCLEOTIDE; APTAMER; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; CARBON; CARBON NANOTUBE; CARMUSTINE; CETUXIMAB; CISPLATIN; CURCUMIN; DENDRIMER; DOXORUBICIN; GEMCITABINE; GOLD NANOPARTICLE; LIPOSOME; OCTREOTIDE; PACLITAXEL; PIMONIDAZOLE; POLYGLACTIN; POLYMER; RITUXIMAB; SALINOMYCIN; SINGLE STRANDED DNA; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE; TEMOZOLOMIDE; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; BREAST METASTASIS; CANCER CELL; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DOWN REGULATION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG TRANSPORT; ENCAPSULATION; HUMAN; IMMUNE RESPONSE; INTERNALIZATION; KAPOSI SARCOMA; MELANOMA; METASTASIS; MICELLE; MOLECULAR INTERACTION; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NANOMEDICINE; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SARCOMA; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ACUTE MYELOID LEUKEMIA; AML; CAM-DR; CANCER STEM CELL; CCP; CELL ADHESION-MEDIATED DRUG RESISTANCE; CENTRAL NERVOUS SYSTEM; CHARGE-CONVERSION POLYMER; CHRONIC LYMPHOCYTIC LEUKEMIA; CLL; CNS; CSC; DRUG DELIVERY; EGFR; ENHANCED PERMEABILITY AND RETENTION; EPIDERMAL GROWTH FACTOR RECEPTOR; EPR; H(2)N-LEU-LEU-LEU-OH; HIF-1; HYPOXIA-INDUCIBLE FACTOR 1; IGF-1R; IL-2; INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR; INTERLEUKIN-2; LLL; MAB; MDR; MONOCLONAL ANTIBODY; MRP; MULTIDRUG RESISTANCE; MULTIDRUG-RESISTANCE-ASSOCIATED PROTEIN; NANOBIOPOLYMERS; NANODRUG; NF-ΚB; NON-SMALL CELL LUNG CANCER; NSCLC; NUCLEAR FACTOR ΚB; PDGFR-Β; PEG; PLATELET-DERIVED GROWTH FACTOR RECEPTOR-Β; POLYETHYLENE GLYCOL; RES; RETICULOENDOTHELIAL SYSTEM; SDF-1/CXCL12; SHORT INTERFERING RNA; SIRNA; STROMAL CELL-DERIVED FACTOR 1; TAT; TEMOZOLOMIDE; TFR; TG2; TISSUE TRANSGLUTAMINASE; TLR; TMZ; TNFΑ; TOLL-LIKE RECEPTOR; TRANSACTIVATOR OF TRANSCRIPTION; TRANSFERRIN RECEPTOR; TUMOR MULTIDRUG RESISTANCE; TUMOR NECROSIS FACTOR Α;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84888200154     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.09.019     Document Type: Review

References (148)

1. Perche F., Torchilin V.P. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J. Drug Deliv. 2013, 2013:705265.
2. Torchilin V.P. Antinuclear antibodies with nucleosome-restricted specificity for targeted delivery of chemotherapeutic agents. Ther. Deliv. 2010, 1:257-272.
3. Yang T., Choi M.K., Cui F.D., Lee S.J., Chung S.J., Shim C.K., Kim D.D. Antitumor effect of paclitaxel-loaded pegylated immunoliposomes against human breast cancer cells. Pharm. Res. 2007, 24:2402-2411.
4. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65:36-48.
5. Needham D., Anyarambhatla G., Kong G., Dewhirst M.W. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000, 60:1197-1201.
6. Hu C.M., Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 2012, 83:1104-1111.
7. Mattheolabakis G., Rigas B., Constantinides P.P. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond.) 2012, 7:1577-1590.
8. Cho K., Wang X., Nie S., Chen Z.G., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14:1310-1316.
9. Minko T. Soluble polymer conjugates for drug delivery. Drug Discov. Today Technol. 2005, 2:15-20.
10. Lim J., Simanek E.E. Triazine dendrimers as drug delivery systems: from synthesis to therapy. Adv. Drug Deliv. Rev. 2012, 64:826-835.
11. Webster D.M., Sundaram P., Byrne M.E. Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics. Eur. J. Pharm. Biopharm. 2013, 84:1-20.
12. Fabbro C., Ali-Boucetta H., Da Ros T., Kostarelos K., Bianco A., Prato M. Targeting carbon nanotubes against cancer. Chem. Commun. (Camb.) 2012, 48:3911-3926.
13. Arvizo R., Bhattacharya R., Mukherjee P. Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin. Drug Deliv. 2010, 7:753-763.
14. Libutti S.K., Paciotti G.F., Byrnes A.A., Alexander H.R., Gannon W.E., Walker M., Seidel G.D., Yuldasheva N., Tamarkin L. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res. 2010, 16:6139-6149.
15. Bhattacharyya S., Kudgus R.A., Bhattacharya R., Mukherjee P. Inorganic nanoparticles in cancer therapy. Pharm. Res. 2011, 28:237-259.
16. Xue X., Liang X.J. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin. J. Cancer 2012, 31:100-109.
17. Dong X., Mumper R.J. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond.) 2010, 5:597-615.
18. Shapira A., Livney Y.D., Broxterman H.J., Assaraf Y.G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat. 2011, 14:150-163.
19. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., Roninson I.B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47:381-389.
20. van Asperen J., van Tellingen O., Tijssen F., Schinkel A.H., Beijnen J.H. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br. J. Cancer 1999, 79:108-113.
21. Shiraki N., Hamada A., Ohmura T., Tokunaga J., Oyama N., Nakano M. Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine. Biol. Pharm. Bull. 2001, 24:555-557.
22. Ye S., MacEachran D.P., Hamilton J.W., O'Toole G.A., Stanton B.A. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif. Am. J. Physiol. Cell Physiol. 2008, 295:C807-C818.
23. Wang J., Wang H., Zhao L., Fan S., Yang Z., Gao F., Chen L., Xiao G.G., Molnár J., Wang Q. Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines. Anticancer Res 2010, 30:3593-3598.
24. Jang S.H., Wientjes M.G., Au J.L. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J. Pharmacol. Exp. Ther. 2001, 298:1236-1242.
25. Kemper E.M., van Zandbergen A.E., Cleypool C., Mos H.A., Boogerd W., Beijnen J.H., van Tellingen O. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin. Cancer Res. 2003, 9:2849-2855.
26. Enokida H., Gotanda T., Oku S., Imazono Y., Kubo H., Hanada T., Suzuki S., Inomata K., Kishiye T., Tahara Y., Nishiyama K., Nakagawa M. Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line. Jpn. J. Cancer Res. 2002, 93:1037-1046.
27. Pires M.M., Emmert D., Hrycyna C.A., Chmielewski J. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol. Pharmacol. 2009, 75:92-100.
28. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
29. Lord C.J., Ashworth A. The DNA damage response and cancer therapy. Nature 2012, 481:287-294.
30. Rebucci M., Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem. Pharmacol. 2013, 85:1219-1226.
31. Kirkin V., Joos S., Zörnig M. The role of bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 2004, 1644:229-249.
32. Bentires-Alj M., Barbu V., Fillet M., Chariot A., Relic B., Jacobs N., Gielen J., Merville M.P., Bours V. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003, 22:90-97.
33. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N.Q., Butler A., Jones D., Raine K., Latimer C., Santos C.R., Nohadani M., Eklund A.C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P.A., Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
34. Landau D.A., Carter S.L., Stojanov P., McKenna A., Stevenson K., Lawrence M.S., Sougnez C., Stewart C., Sivachenko A., Wang L., Wan Y., Zhang W., Shukla S.A., Vartanov A., Fernandes S.M., Saksena G., Cibulskis K., Tesar B., Gabriel S., Hacohen N., Meyerson M., Lander E.S., Neuberg D., Brown J.R., Getz G., Wu C.J. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013, 152:714-726.
35. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
36. Park C.H., Bergsagel D.E., McCulloch E.A. Mouse myeloma tumor stem cells: a primary cell culture assay. J. Natl. Cancer Inst. 1971, 46:411-422.
37. Hamburger A.W., Salmon S.E. Primary bioassay of human tumor stem cells. Science 1977, 197:461-463.
38. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
39. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
40. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3983-3988.
41. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
42. Taylor M.D., Poppleton H., Fuller C., Su X., Liu Y., Jensen P., Magdaleno S., Dalton J., Calabrese C., Board J., Macdonald T., Rutka J., Guha A., Gajjar A., Curran T., Gilbertson R.J. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005, 8:323-335.
43. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
44. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
45. Hope K.J., Jin L., Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 2004, 5:738-743.
46. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
47. Prince M.E., Sivanandan R., Kaczorowski A., Wolf G.T., Kaplan M.J., Dalerba P., Weissman I.L., Clarke M.F., Ailles L.E. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:973-978.
48. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
49. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
50. Dempke W.C., Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur. J. Cancer 2009, 45:1117-1128.
51. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Jänne P.A., Joshi V.A., McCollum D., Evans T.L., Muzikansky A., Kuhlmann G.L., Han M., Goldberg J.S., Settleman J., Iafrate A.J., Engelman J.A., Haber D.A., Johnson B.E., Lynch T.J. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 2008, 26:2442-2449.
52. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
53. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:13306-13311.
54. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
55. Fukui T., Mitsudomi T. Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen. Thorac. Cardiovasc. Surg. 2008, 56:97-103.
56. Pao W., Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 2005, 23:2556-2568.
57. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
58. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
59. Montagut C., Dalmases A., Bellosillo B., Crespo M., Pairet S., Iglesias M., Salido M., Gallen M., Marsters S., Tsai S.P., Minoche A., Seshagiri S., Somasekar S., Serrano S., Himmelbauer H., Bellmunt J., Rovira A., Settleman J., Bosch F., Albanell J. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 2012, 18:221-223.
60. Ljubimova J.Y., Portilla-Arias J., Patil R., Ding H., Inoue S., Markman J.L., Rekechenetskiy A., Konda B., Gangalum P.R., Chesnokova A., Ljubimov A.V., Black K.L., Holler E. Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple negative breast cancer treatment. J. Drug Target. 2013, (in press).
61. Trédan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
62. Hazlehurst L.A., Dalton W.S. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 2001, 20:43-50.
63. Weaver V.M., Lelièvre S., Lakins J.N., Chrenek M.A., Jones J.C., Giancotti F., Werb Z., Bissell M.J. β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002, 2:205-216.
64. Cowan D.S., Tannock I.F. Factors that influence the penetration of methotrexate through solid tissue. Int. J. Cancer 2001, 91:120-125.
65. Raghunand N., Mahoney B.P., Gillies R.J. Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem. Pharmacol. 2003, 66:1219-1229.
66. Mahoney B.P., Raghunand N., Baggett B., Gillies R.J. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem. Pharmacol. 2003, 66:1207-1218.
67. Davies CeL, Berk D.A., Pluen A., Jain R.K. Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br. J. Cancer 2002, 86:1639-1644.
68. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000, 60:2497-2503.
69. Vinogradov S., Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond.) 2012, 7:597-615.
70. Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di Tomaso E., Jain R.K. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427:695.
71. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002, 62:3387-3394.
72. Wang G.L., Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 1995, 270:1230-1237.
73. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 2000, 35:71-103.
74. Milane L., Ganesh S., Shah S., Duan Z.F., Amiji M. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J. Control. Release 2011, 155:237-247.
75. Chung A.S., Wu X., Zhuang G., Ngu H., Kasman I., Zhang J., Vernes J.M., Jiang Z., Meng Y.G., Peale F.V., Ouyang W., Ferrara N. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 2013, 19:1114-1123.
76. Ding H., Inoue S., Ljubimov A.V., Patil R., Portilla-Arias J., Hu J., Konda B., Wawrowsky K.A., Fujita M., Karabalin N., Sasaki T., Black K.L., Holler E., Ljubimova J.Y. Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with ph-dependent drug release [corrected]. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18143-18148.
77. Huang Y., Goel S., Duda D.G., Fukumura D., Jain R.K. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013, 73:2943-2948.
78. Wang M., Thanou M. Targeting nanoparticles to cancer. Pharmacol. Res. 2010, 62:90-99.
79. Prabhakar U., Maeda H., Jain R.K., Sevick-Muraca E.M., Zamboni W., Farokhzad O.C., Barry S.T., Gabizon A., Grodzinski P., Blakey D.C. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013, 73:2412-2417.
80. Koziara J.M., Whisman T.R., Tseng M.T., Mumper R.J. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control. Release 2006, 112:312-319.
81. Rouf M.A., Vural I., Renoir J.M., Hincal A.A. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J. Liposome Res. 2009, 19:322-331.
82. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54:987-992.
83. Zhang Y., Zhang H., Wang X., Wang J., Zhang X., Zhang Q. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 2012, 33:679-691.
84. Gottstein C., Wu G., Wong B.J., Zasadzinski J.A. Precise quantification of nanoparticle internalization. ACS Nano 2013, 7(6):4933-4945.
85. Krown S.E., Northfelt D.W., Osoba D., Stewart J.S. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin. Oncol. 2004, 31:36-52.
86. Rose P.G. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005, 10:205-214.
87. Sonneveld P., Hajek R., Nagler A., Spencer A., Bladé J., Robak T., Zhuang S.H., Harousseau J.L., Orlowski R.Z., DOXIL-MMY-3001 Study Investigators Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008, 112:1529-1537.
88. Collea R.P., Kruter F.W., Cantrell J.E., George T.K., Kruger S., Favret A.M., Lindquist D.L., Melnyk A.M., Pluenneke R.E., Shao S.H., Crockett M.W., Asmar L., O'Shaughnessy J. Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study. Ann. Oncol. 2012, 23:2599-2605.
89. Montanari M., Fabbri F., Rondini E., Frassineti G.L., Mattioli R., Carloni S., Scarpi E., Zoli W., Amadori D., Cruciani G. Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori 2012, 98:696-701.
90. Wang R., Xiao R., Zeng Z., Xu L., Wang J. Application of poly(ethylene glycol)-distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives as nanomaterials in drug delivery. Int. J. Nanomedicine 2012, 7:4185-4198.
91. Vijayakumar M.R., Muthu M.S., Singh S. Copolymers of poly(lactic acid) and D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicines: versatile multifunctional platforms for cancer diagnosis and therapy. Expert Opin. Drug Deliv. 2013, 10:529-543.
92. Kaminskas L.M., Porter C.J. Targeting the lymphatics using dendritic polymers (dendrimers). Adv. Drug Deliv. Rev. 2011, 63:890-900.
93. Taratula O., Garbuzenko O., Savla R., Wang Y.A., He H., Minko T. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr. Drug Deliv. 2011, 8:59-69.
94. Knop K., Hoogenboom R., Fischer D., Schubert U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 2010, 49:6288-6308.
95. Leget G.A., Czuczman M.S. Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 1998, 10:548-551.
96. Brenner T.L., Adams V.R. First MAb approved for treatment of metastatic breast cancer. J. Am. Pharm. Assoc. (Wash) 1999, 39:236-238.
97. Goodman L. Persistence-luck-avastin. J. Clin. Invest. 2004, 113:934.
98. Humblet Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin. Pharmacother. 2004, 5:1621-1633.
99. Zhang P., Hu L., Yin Q., Feng L., Li Y. Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy. Mol. Pharm. 2012, 9:1590-1598.
100. Wang W., Zhou F., Ge L., Liu X., Kong F. Transferrin-PEG-PE modified dexamethasone conjugated cationic lipid carrier mediated gene delivery system for tumor-targeted transfection. Int. J. Nanomedicine 2012, 7:2513-2522.
101. Daniels T.R., Bernabeu E., Rodríguez J.A., Patel S., Kozman M., Chiappetta D.A., Holler E., Ljubimova J.Y., Helguera G., Penichet M.L. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 1820, 2012:291-317.
102. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
103. Xiao Z., Farokhzad O.C. Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. ACS Nano 2012, 6:3670-3676.
104. Weis S.M., Cheresh D.A. αV integrins in angiogenesis and cancer. Cold Spring Harb. Perspect. Med. 2011, 1:a006478.
105. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv. Mater. 2012, 24:3747-3756.
106. Gregorc V., Citterio G., Vitali G., Spreafico A., Scifo P., Borri A., Donadoni G., Rossoni G., Corti A., Caligaris-Cappio F., Del Maschio A., Esposito A., De Cobelli F., Dell'Acqua F., Troysi A., Bruzzi P., Lambiase A., Bordignon C. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur. J. Cancer 2010, 46:198-206.
107. Pichon C., Billiet L., Midoux P. Chemical vectors for gene delivery: uptake and intracellular trafficking. Curr. Opin. Biotechnol. 2010, 21:640-645.
108. Pittella F., Zhang M., Lee Y., Kim H.J., Tockary T., Osada K., Ishii T., Miyata K., Nishiyama N., Kataoka K. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and peg-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. Biomaterials 2011, 32:3106-3114.
109. Lee E.S., Gao Z., Kim D., Park K., Kwon I.C., Bae Y.H. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J. Control. Release 2008, 129:228-236.
110. Mohri M., Nitta H., Yamashita J. Expression of multidrug resistance-associated protein (MRP) in human gliomas. J. Neurooncol. 2000, 49:105-115.
111. Patil R., Portilla-Arias J., Ding H., Inoue S., Konda B., Hu J., Wawrowsky K.A., Shin P.K., Black K.L., Holler E., Ljubimova J.Y. Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(β-L-malic acid). Pharm. Res. 2010, 27:2317-2329.
112. Patil R., Portilla-Arias J., Ding H., Konda B., Rekechenetskiy A., Inoue S., Black K.L., Holler E., Ljubimova J.Y. Cellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano vehicle based on poly(β-L-malic acid). Int. J. Mol. Sci. 2012, 13:11681-11693.
113. Yuan H., Li X., Wu J., Li J., Qu X., Xu W., Tang W. Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance. Curr. Med. Chem. 2008, 15:470-476.
114. Wu J., Lu Y., Lee A., Pan X., Yang X., Zhao X., Lee R.J. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 2007, 10:350-357.
115. Ganta S., Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 2009, 6:928-939.
116. Saad M., Garbuzenko O.B., Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond.) 2008, 3:761-776.
117. Bajelan E., Haeri A., Vali A.M., Ostad S.N., Dadashzadeh S. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. J. Pharm. Pharm. Sci. 2012, 15:568-582.
118. Wang K., Wu X., Wang J., Huang J. Cancer stem cell theory: therapeutic implications for nanomedicine. Int. J. Nanomedicine 2013, 8:899-908.
119. Tang Q.L., Zhao Z.Q., Li J.C., Liang Y., Yin J.Q., Zou C.Y., Xie X.B., Zeng Y.X., Shen J.N., Kang T., Wang J. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 2011, 311:113-121.
120. Verma A., Guha S., Diagaradjane P., Kunnumakkara A.B., Sanguino A.M., Lopez-Berestein G., Sood A.K., Aggarwal B.B., Krishnan S., Gelovani J.G., Mehta K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin. Cancer Res. 2008, 14:2476-2483.
121. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
122. Burger J.A., Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23:43-52.
123. Prakash J., de Jong E., Post E., Gouw A.S., Beljaars L., Poelstra K. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier. J. Control. Release 2010, 145:91-101.
124. Goldsmith M., Mizrahy S., Peer D. Grand challenges in modulating the immune response with RNAi nanomedicines. Nanomedicine (Lond.) 2011, 6:1771-1785.
125. Poeck H., Besch R., Maihoefer C., Renn M., Tormo D., Morskaya S.S., Kirschnek S., Gaffal E., Landsberg J., Hellmuth J., Schmidt A., Anz D., Bscheider M., Schwerd T., Berking C., Bourquin C., Kalinke U., Kremmer E., Kato H., Akira S., Meyers R., Häcker G., Neuenhahn M., Busch D., Ruland J., Rothenfusser S., Prinz M., Hornung V., Endres S., Tüting T., Hartmann G. 5'-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 2008, 14:1256-1263.
126. Kortylewski M., Swiderski P., Herrmann A., Wang L., Kowolik C., Kujawski M., Lee H., Scuto A., Liu Y., Yang C., Deng J., Soifer H.S., Raubitschek A., Forman S., Rossi J.J., Pardoll D.M., Jove R., Yu H. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 2009, 27:925-932.
127. Khairuddin N., Gantier M.P., Blake S.J., Wu S.Y., Behlke M.A., Williams B.R., McMillan N.A. siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol. Cell Biol. 2012, 90:187-196.
128. Ding H., Helguera G., Rodríguez J.A., Markman J., Luria-Pérez R., Gangalum P., Portilla-Arias J., Inoue S., Daniels-Wells T.R., Black K., Holler E., Penichet M.L., Ljubimova J.Y. Polymalic acid nanobioconjugate for simultaneous inhibition of tumor growth and immunostimulation in HER2/neu-positive breast cancer. J. Control. Release 2013 Nov 10, 171(3):322-329.
129. Yu H., Xu Z., Chen X., Xu L., Yin Q., Zhang Z., Li Y. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel. Macromol. Biosci. 2013, (in press).
130. Qian L., Zheng J., Wang K., Tang Y., Zhang X., Zhang H., Huang F., Pei Y., Jiang Y. Cationic core-shell nanoparticles with carmustine contained within o(6)-benzylguanine shell for glioma therapy. Biomaterials 2013, 34:8968-8978.
131. Chang P.Y., Peng S.F., Lee C.Y., Lu C.C., Tsai S.C., Shieh T.M., Wu T.S., Tu M.G., Chen M.Y., Yang J.S. Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells. Int. J. Oncol. 2013, 43:1141-1150.
132. Burke A.R., Singh R.N., Carroll D.L., Wood J.C., D'Agostino R.B., Ajayan P.M., Torti F.M., Torti S.V. The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials 2012, 33:2961-2970.
133. Zhao S., Tan S., Guo Y., Huang J., Chu M., Liu H., Zhang Z. Ph-sensitive docetaxel-loaded D-α-tocopheryl polyethylene glycol succinate-poly(β-amino ester) copolymer nanoparticles for overcoming multidrug resistance. Biomacromolecules 2013, 14:2636-2646.
134. Swaminathan S.K., Roger E., Toti U., Niu L., Ohlfest J.R., Panyam J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J. Control. Release 2013 Nov 10, 171(3):280-287.
135. Zhou J., Patel T.R., Sirianni R.W., Strohbehn G., Zheng M.Q., Duong N., Schafbauer T., Huttner A.J., Huang Y., Carson R.E., Zhang Y., Sullivan D.J., Piepmeier J.M., Saltzman W.M. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:11751-11756.
136. Zhang X., Yang H., Gu K., Chen J., Rui M., Jiang G.L. In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer. Int. J. Nanomedicine 2011, 6:437-444.
137. Yin Q., Shen J., Zhang Z., Yu H., Chen L., Gu W., Li Y. Multifunctional nanoparticles improve therapeutic effect for breast cancer by simultaneously antagonizing multiple mechanisms of multidrug resistance. Biomacromolecules 2013, 14:2242-2252.
138. Yang C., Xiong F., Wang J., Dou J., Chen J., Chen D., Zhang Y., Luo S., Gu N. Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma. Nanomedicine (Lond.) 2013, (in press).
139. Perlstein B., Finniss S.A., Miller C., Okhrimenko H., Kazimirsky G., Cazacu S., Lee H.K., Lemke N., Brodie S., Umansky F., Rempel S.A., Rosenblum M., Mikklesen T., Margel S., Brodie C. TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. Neuro Oncol. 2013, 15:29-40.
140. Wang D., Tang J., Wang Y., Ramishetti S., Fu Q., Racette K., Liu F. Multifunctional nanoparticles based on a single-molecule modification for the treatment of drug-resistant cancer. Mol. Pharm. 2013, 10:1465-1469.
141. Gaca S., Reichert S., Rödel C., Rödel F., Kreuter J. Survivin-miRNA-loaded nanoparticles as auxiliary tools for radiation therapy: preparation, characterisation, drug release, cytotoxicity and therapeutic effect on colorectal cancer cells. J. Microencapsul. 2012, 29:685-694.
142. Kato S., Kimura M., Kageyama K., Tanaka H., Miwa N. Enhanced radiosensitization by liposome-encapsulated pimonidazole for anticancer effects on human melanoma cells. J. Nanosci. Nanotechnol. 2012, 12:4472-4477.
143. Dreaden E.C., Gryder B.E., Austin L.A., Tene Defo B.A., Hayden S.C., Pi M., Quarles L.D., Oyelere A.K., El-Sayed M.A. Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Bioconjug. Chem. 2012, 23:1507-1512.
144. 4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice. Int. J. Nanomedicine 2013, 8:1439-1449.
145. Günther H.S., Schmidt N.O., Phillips H.S., Kemming D., Kharbanda S., Soriano R., Modrusan Z., Meissner H., Westphal M., Lamszus K. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008, 27:2897-2909.
146. Borsellino N., Belldegrun A., Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995, 55:4633-4639.
147. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
148. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.